Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2020 / Mar / Quick News on COVID-19
Microbiology & Immunology Microbiology and Immunology Point of care testing Microscopy and imaging Biochemistry and molecular biology Infectious Disease

Quick News on COVID-19

By Luke Turner 03/24/2020 Quick Read (pre 2022) 1 min read

Share

A £46 million international COVID-19 prevention and research package has been launched in the UK, of which £1 million was awarded to Mologic to develop a rapid, handheld diagnostic device. Should they succeed, healthcare professionals will be able to run COVID-19 tests in the community and receive results in as little as 10 minutes (1).

A worldwide 3D printing manufacturer has decided to offer hospitals, medical centers, and scientific institutes access to its 63 machines. BCN3D made the announcement in the hope that innovators around the globe will use the printing machines to find new ways to combat the COVID-19 pandemic, including the manufacture of new respiratory equipment (2).

The pathology of the early phase of COVID-19 pneumonia has been described for the first time. Two patients who had recently undergone lung lobectomies were retrospectively diagnosed with COVID-19 at the time of surgery. Both exhibited edema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration, and multinucleated giant cells. Fibroblastic plugs were noted in airspaces (3).

In a preliminary report, a team of researchers have described a human monoclonal antibody that neutralizes SARS-CoV-2. 47D11, a cross-neutralizing antibody, targets a communal epitope on the spike receptor 104 binding domain. With further studies, it is hoped that the antibody will facilitate the development of antigen detection tests (4).

Approximately 86 percent of all COVID-19 infections in China were undocumented before travel restrictions were imposed on January 23, 2020. That’s according to a new study estimating that undocumented infections were responsible for 79 percent of documented cases, underlining the rapid geographic spread of SARS-CoV-2 and the challenge of containment (5).

Highly respected University of Washington pathologist Stephen Schwartz died Tuesday, March 17, after hospitalization for COVID-19. Schwartz was well-known for his groundbreaking work on smooth muscle cell and blood vessel biology. “He has left a lasting imprint on our department, our university, and the broader scientific community,” the university stated publicly (6).

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Mologic (2020). Available at: https://bit.ly/394MLFD.
  2. BCN3D (2020). Available at: https://bit.ly/2x6k8e2.
  3. S Tian et al., 2020. PMID: 32114094.
  4. C Wang (2020). Available at: https://bit.ly/2xQtdrV.
  5. R Li, Science, [Epub ahead of print] (2020). PMID: 32179701.
  6. University of Washington Department of Pathology (2020). Available at: https://bit.ly/3988DAl.

About the Author(s)

Luke Turner

While completing my undergraduate degree in Biology, I soon discovered that my passion and strength was for writing about science rather than working in the lab. My master’s degree in Science Communication allowed me to develop my science writing skills and I was lucky enough to come to Texere Publishing straight from University. Here I am given the opportunity to write about cutting edge research and engage with leading scientists, while also being part of a fantastic team!

More Articles by Luke Turner

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

The Viral Frontier
Infectious Disease
The Viral Frontier

January 23, 2024

1 min read

The latest on the UK COVID-19 inquiry

What’s New in Infectious Disease? (December 2021)
Infectious Disease
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

Immunology Insights
Infectious Disease
Immunology Insights

January 13, 2022

1 min read

The latest research in pathology and laboratory medicine

Pneumocystis Mysteries
Infectious Disease
Pneumocystis Mysteries

January 21, 2022

1 min read

What is the correct name for this pneumonia-causing pathogen?

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.